Unknown

Dataset Information

0

The Rheumatology Drugs for COVID-19 Management: Which and When?


ABSTRACT:

Introduction

While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1?, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-?, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents a game-changer option. In this article, we will review the drugs that have indication in patients with COVID-19, including corticosteroids, antimalarials, anti-TNF, anti-IL-1, anti-IL-6, baricitinib, intravenous immunoglobulins, and colchicine. The PubMed, Medline, and Cochrane Library databases were searched for English-language papers concerning COVID-19 treatment published between January 2020 and October 2020. Results were summarized as a narrative review due to large heterogeneity among studies. In the absence of specific treatments, the use of immunomodulatory drugs could be advisable in severe COVID-19 patients, but clinical outcomes are still suboptimal. An early detection and treatment of the complications combined with a multidisciplinary approach could allow a better recovery of these patients.

SUBMITTER: Atzeni F 

PROVIDER: S-EPMC7919806 | biostudies-literature | 2021 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications


<h4>Introduction</h4>While waiting for the development of specific antiviral therapies and vaccines to effectively neutralize the SARS-CoV2, a relevant therapeutic strategy is to counteract the hyperinflammatory status, characterized by an increase mainly of interleukin (IL)-1β, IL-2, IL-6, IL-7, IL-8, and tumor necrosis factor (TNF)-α, which hallmarks the most severe clinical cases. 'Repurposing' immunomodulatory drugs and applying clinical management approved for rheumatic diseases represents  ...[more]

Similar Datasets

| S-EPMC7508523 | biostudies-literature
| S-EPMC7270517 | biostudies-literature
| S-EPMC8156524 | biostudies-literature
| S-EPMC7832421 | biostudies-literature
| S-EPMC7665741 | biostudies-literature
| S-BSST563 | biostudies-other
| 2340209 | ecrin-mdr-crc
| S-EPMC7193144 | biostudies-literature
| S-EPMC7537960 | biostudies-literature